The first enantioselective synthesis of chiral isosteric phosphonate analogues of FTY720 is described. One of these analogues, FTY720-(E)-vinylphosphonate (S)-5, but not its R enantiomer, elicited a potent antiapoptotic effect in intestinal epithelial cells, suggesting that it exerts its action via the enantioselective activation of a receptor. (S)-5 failed to activate the sphingosine 1-phosphate type 1 (S1P 1 ) receptor. ethyl]-1,3-propanediol, Fingolimod, 1, Chart 1) is a synthetic analogue of the chiral sphingolipid myriocin (2). 1 As an analogue of sphingosine, FTY720 is phosphorylated in vivo by sphingosine kinases, affording (S)-FTY720-phosphate (3), which activates four of the five known sphingosine 1-phosphate (S1P, 2a) G proteincoupled receptors.
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Internalization and subsequent polyubiquitination of the S1P receptors leads to their proteasomal degradation and renders the cells unresponsive to S1P; therefore, lymphocytes are not capable of recirculation to peripheral inflammatory tissues. 3 Thus, FTY720 has therapeutic potential and, in fact, is the first S1P receptor modulator that has entered the stage of a phase-III clinical study. 4 Several syntheses of 1 5 and of phosphate 3 have been accomplished. 6 In contrast to phosphates such as 3, phosphonate analogues are resistant to the action of lipid phosphate phosphatases and may offer improved cellular stability. A racemic mixture of the nonhydrolyzable phosphonate analogue of FTY720 (4) was reported in which the C-O-P bond is replaced with a C-C-P bond; 2b rac-4 was found to be a high-affinity agonist of the S1P-type 1 receptor (S1P 1 ), with a similar potency as (S)-3. 7 We report here the first asymmetric syntheses of the chiral phosphonate analogues of FTY720, (R)-4 and (S)-4. Oxazoline intermediate (S)-14 (Scheme 1), prepared by a modification of our previous route, 6c was further elaborated to give the corresponding (E)-vinylphosphonate analogue (S)-5. We have included a preliminary pharmacological characterization of the effects of these analogues on the nontransformed rat intestinal epithelial cell line IEC-6. This study revealed that (S)-5, but not its (R) enantiomer, exerts a potent antiapoptotic effect in a camptothecin (CPT)-induced apoptosis model. 8 Unlike phosphate (S)-3, (S)-5 did not activate the S1P 1 receptor of the Endothelial Differentiation Gene (EDG) family of G proteincoupled receptors, making it a novel enantioselective probe activating a cytoprotective mechanism against apoptosis induced by DNA damage.
Wittig reaction of 4-bromobenzaldehyde with the ylide of n-heptyltriphenylphosphonium bromide gave arylalkene 6 as an E,Z (1:3) mixture (Scheme 1). Sonogashira coupling between 6 and 4-(phenylmethoxy)-1-butyne delivered enyne 7 as a 1:3 E:Z mixture in 92% yield. Alcohol 8 was obtained on reduction of the unsaturated bonds and hydrogenolysis of the O-benzyl group in the presence of Pearlman's catalyst. After Swern oxidation of 8 provided aldehyde 9, use of a Mannich reagent, Eschenmoser's salt, 9 afforded R-methylene aldehyde 10. Reduction of 10 with NaBH 4 in the presence of CeCl 3 (to suppress conjugate reduction) gave allyl alcohol 11.
10 CeCl 3 , which is a mild Lewis acid, is not required, since CsCl also provided 11 as the only product. Asymmetric Sharpless epoxidation 11 of 11 with cumene hydroperoxide (CHP) in the presence of L-(+)-DIPT, Ti(OPr-i) 4 , and molecular sieves gave epoxide (S)-12.
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The synthesis of (S)-12 was accomplished in 7 steps from p-bromobenzaldehyde and in 46% overall yield. Reaction of alcohol (S)-12 with trichloroacetonitrile in the presence of DBU gave 2,3-epoxy-1-trichloroacetimidate (R)-13. The tetrasubstituted carbon in oxazoline 14 was set up bearing the desired nitrogen substituent by opening of epoxide (R)-13 with catalytic Et 2 AlCl, 13 affording (S)-14 in 74% yield for the two steps. Swern oxidation of oxazoline (S)-14 gave oxazoline aldehyde 15 (Scheme 2), which on Horner-Wadsworth-Emmons reaction with tetramethyl methylenediphosphonate afforded ester (S)-16 in 87% yield and with an E/Z ratio of ∼10:1. Simultaneous demethylation and release of the hydroxy and amino groups by treatment with trimethylsilyl bromide (TMSBr) provided (S)-5, but the yield was low. Therefore, the hydroxy and amino groups were first released by treatment with 1 M HCl. After the amine hydrochloride was neutralized (saturated aq Na 2 CO 3 ), amino alcohol 17 was converted to (S)-5 with TMSBr followed by 95% methanol; 84% yield for the two steps. Reduction of (S)-5 using Pearlman's catalyst gave (S)-4.
Asymmetric epoxidation of 11 with D-(-)-DIPT gave epoxide (R)-12, which was converted via (R)-14 to (R)-5 in six steps (Scheme 3). Catalytic hydrogenation of (R)-5 afforded (R)-4. S1P promotes the survival of many cell types. 14 Both 2a and (S)-3 protect oligodendrocyte progenitor cells from apoptotic cell death in response to growth factor withdrawal, and (S)-3 was also shown to be cytoprotective in response to pro-apoptotic (9) cytokines and microglial activation. 15 The ability of 2a, (S)-3, and phosphonate analogues 4 and 5 to protect IEC-6 cells from apoptotic cell death in response to the topoisomerase inhibitor CPT was assessed by DNA fragmentation. Pretreatment with 2a, (S)-3, (R)-4, or (R)-5 did not result in a significant reduction in DNA fragmentation in response to a 4-h treatment with 20 µM CPT. However, we found that the cytoprotective effect was enantioselective, since pretreatment with 1 µM of (S)-4 or (S)-5 showed a significant reduction (21 and 50%, respectively) in DNA fragmentation in response to CPT.
In a preliminary study of the activity of the FTY720-phosphonate analogues on S1P receptors, we performed Ca 2+ mobilization assays with HTC4 cells that were stably transfected with S1P 1 . As shown in Figure 1 , the S1P 1 transfectants were activated by (S)-3 to 76% of the maximal S1P-induced activation, and displayed a similar potency as S1P (13 ( 2 nM for S1P vs 9 ( 1 nM for (S)-3). (R)-5 and (R)-4 both showed a modest activity against S1P 1 with E max values that ranged from 73 to 93% of the maximal S1P-induced responses, and EC 50 values that were increased by ∼2-to 3-fold. (S)-4 activated S1P 1 to 36% of the maximal S1P-induced response, and the EC 50 value was increased by ∼5-fold to 75 ( 21 nM. Since (S)-5 did not elicit a Ca 2+ response from cells transfected with the S1P 1 receptor, we conclude that the potent cytoprotective effect of (S)-5 is not mediated by S1P 1 .
In conclusion, we have described the synthesis of the enantiomers of FTY720 phosphonate analogues 4 and 5. (S)-4 and (S)-5, but not 2a or (S)-3, all at 1 µM, protected IEC-6 cells from apoptosis. The extent of CPT-induced DNA fragmentation was reduced by 50% and 21% in the presence of 1 µM of (S)-5 and (S)-4, respectively. The potent cytoprotective activity of (S)-5 is not mediated by S1P 1 . Experiments are underway to characterize the cellular effects of these analogues.
Experimental Section (2S)-2-(2′-(Trichloromethyl)-4′,5′-dihydrooxazol-5-yl)-4-(4′′-octylphenyl)-butan-1-ol [(S)-(+)-14].
To a solution of 435 mg (1.5 mmol) of epoxy alcohol (S)-12 in 25 mL of CH 2 Cl 2 at 0°C were added Cl 3 CCN (0.17 mL, 1.65 mmol) and DBU (0.023 mL, 0.15 mmol). After being stirred at 0°C for 1.5 h, the reaction mixture was diluted with Et 2 O (20 mL) and water (20 mL). The organic layer was separated, washed with brine (20 mL), dried (MgSO 4 ), and concentrated. The residue was purified by chromatography (hexane/EtOAc 20:1) to give 565 mg (87%) of (R)-13; R f 0.58 (EtOAc/hexane 1:3). To an ice-cold solution of 565 mg (1.31 mmol) of (R)-13 in 20 mL of CH 2 Cl 2 was added Et 2 AlCl (0.75 mL, 0.75 mmol, a 1.0 M solution in hexane). After the mixture was stirred at 0°C for 20 min and then at rt for 3 h, the reaction was quenched with saturated aq NaHCO 3 solution (20 mL). The organic layer was washed with brine (20 mL), dried (MgSO 4 ), and concentrated. The residue was purified by chromatography (hexane/EtOAc 3:1) to give 480 mg (85%) of (S)-14 as a white solid; mp 56.7-57.5°C
; 2, 22.7, 29.3, 29.4, 29.5, 29.8, 31.6, 32.0, 35.6, 37.6, 66.8, 76.0, 86.5, 128.2, 128.9, 138.2, 140.8, 163 13 C NMR (CDCl 3 ) δ 14. 1, 22.7, 29.0, 29.3, 29.5, 29.7, 31.6, 31.9, 35.5, 37.5, 67.0, 75.9, 86.4, 128.1, 128.6, 138.1, 140.9, 163.3 .
(
3S)-3-(Amino)-3-(hydroxymethyl)-5-(4′-octylphenyl)-pent-(1E)-enyl-phosphonic acid [(S)-(+)-5].
To a solution of 269 mg (0.50 mmol) of (S)-16 in 10 mL of THF at rt was added 3 mL of 1 M HCl. After the reaction mixture was stirred overnight, the solvent was evaporated and the residue was extracted with a mixture of CHCl 3 and saturated Na 2 CO 3 aq solution. The organic phase was dried (MgSO 4 ) and concentrated. 3H), 5.93 (dd, 1H, J ) 20.0, 17.6 Hz), 6.85 (dd, 1H, J ) 22.8, 17.6 Hz), 4H); 13 C NMR (CDCl 3 ) δ 14. 1, 22.7, 29.3, 29.36, 29.44, 29.5, 31.6, 31.9, 35.5, 39.4, 52.4 (d, J ) 13 C NMR (CDCl 3 ) δ 14. 1, 22.7, 29.3, 29.4, 29.42, 29.5, 29.7, 31.6, 31.9, 35.5, 39.4, 52.4 1, 128.4, 128.5, 138.7, 140.7, 157 .9 (d, J ) 6.0 Hz); 31 P NMR (CDCl 3 ) δ 21.8. To a solution of (S)-17 in 10 mL of dry CH 2 Cl 2 at rt was added 0.66 mL (5.0 mmol) of TMSBr. After the reaction mixture was stirred for 4 h, the solvent was removed, and the residue was dried and dissolved in 2 mL of 95% MeOH with stirring for 1 h. Removal of the solvent afforded 224 mg (93%) of ( 13 C NMR (CDCl 3 /CD 3 OD 9:1) δ 14. 1, 22.9, 29.1, 29.5, 29.6, 31.8, 32.3, 35.8, 36.5, 62.2 (d, J ) 20.1 Hz), 64.4, 123.3, 125.2, 128.3, 128.9, 137.6, 141.4, 144 C NMR (CDCl 3 / CD 3 OD 9:1) δ 14. 2, 22.9, 29.0, 29.5, 29.6, 29.7, 29.9, 31.8, 32.3, 35.8, 36.5, 62.2 (d, J ) 20.1 Hz), 64.4, 123.4, 125.2, 128.3, 128.9, 137.6, 141.4, 144.2;  31 P NMR (CDCl 3 /CD 3 OD 9:1) δ 13.1.
